Therapeutic Drug Monitoring in Hidradenitis Suppurativa Patients With Suboptimal Treatment Response to Adalimumab
In HS patients with suboptimal response to standard adalimumab dosing, a significant number of patients have subtherapeutic drug levels with a minority of those having anti-adalimumab antibodies. TDM can be helpful in identifying HS patients with subtherapeutic drug levels and without antidrug antibodies who could potentially benefit from dose escalation.
Authors
- Hannah Stirton (ORCID: https://orcid.org/0000-0001-5592-0240)
- Raed Alhusayen (ORCID: https://orcid.org/0000-0001-6506-9568)
Institutions
- Sunnybrook Health Science Centre (CA)
- University of Toronto (CA)
- Health Sciences Centre (CA)
Publication Details
- Journal
- Journal of Cutaneous Medicine and Surgery
- Published
- 2025-05-23
- DOI
- https://doi.org/10.1177/12034754251341846
- Citations
- 1
- Primary Topic
- Hidradenitis Suppurativa and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.00